GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pangen Biotech Inc (XKRX:222110) » Definitions » Cyclically Adjusted Revenue per Share

Pangen Biotech (XKRX:222110) Cyclically Adjusted Revenue per Share : ₩691.31 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Pangen Biotech Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pangen Biotech's adjusted revenue per share for the three months ended in Mar. 2025 was ₩266.808. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩691.31 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-07-08), Pangen Biotech's current stock price is ₩5900.00. Pangen Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩691.31. Pangen Biotech's Cyclically Adjusted PS Ratio of today is 8.53.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Pangen Biotech was 10.19. The lowest was 6.81. And the median was 8.22.


Pangen Biotech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Pangen Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangen Biotech Cyclically Adjusted Revenue per Share Chart

Pangen Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 662.80

Pangen Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 654.83 662.80 691.31

Competitive Comparison of Pangen Biotech's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Pangen Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangen Biotech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pangen Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pangen Biotech's Cyclically Adjusted PS Ratio falls into.


;
;

Pangen Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pangen Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=266.808/122.5900*122.5900
=266.808

Current CPI (Mar. 2025) = 122.5900.

Pangen Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 236.377 100.051 289.628
201509 129.349 100.111 158.393
201512 212.935 100.220 260.463
201603 63.569 100.561 77.495
201606 24.611 100.791 29.934
201609 43.030 101.461 51.991
201612 48.849 101.561 58.963
201703 39.258 102.851 46.793
201706 100.488 102.611 120.053
201709 99.787 103.491 118.203
201712 11.912 102.991 14.179
201803 46.840 104.101 55.159
201806 203.000 104.130 238.987
201809 175.730 105.651 203.906
201812 165.664 104.351 194.620
201903 44.335 104.491 52.014
201906 73.215 104.881 85.577
201909 97.084 105.200 113.132
201912 84.151 105.121 98.135
202003 141.275 105.354 164.387
202006 255.050 105.112 297.460
202009 142.083 106.198 164.015
202012 102.878 105.765 119.243
202103 87.722 107.357 100.169
202106 199.243 107.579 227.045
202109 332.403 108.759 374.674
202112 132.703 109.676 148.328
202203 251.194 111.848 275.319
202206 81.665 114.072 87.763
202209 183.090 114.715 195.658
202212 92.045 115.179 97.967
202303 68.619 116.507 72.201
202306 263.341 117.182 275.494
202309 186.909 118.964 192.607
202312 296.855 118.837 306.230
202403 312.507 120.123 318.925
202406 189.649 120.007 193.730
202409 402.541 120.861 408.299
202412 354.885 121.135 359.147
202503 266.808 122.590 266.808

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Pangen Biotech  (XKRX:222110) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pangen Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5900.00/691.31
=8.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Pangen Biotech was 10.19. The lowest was 6.81. And the median was 8.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pangen Biotech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pangen Biotech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangen Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
4Floor Innoplex 2-dong, 306 Sinwon-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, KOR, 16675
Pangen Biotech Inc is a biotechnology company. It is engaged in development of biosimilar products and technology transfer services for biologics development. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc.

Pangen Biotech Headlines

No Headlines